Rtw Investments Adds $5M in Milestone Pharmaceuticals Inc. ($MIST)

RTW Investments recently boosted its holdings in Milestone Pharmaceuticals Inc. (NasdaqGS: MIST), increasing its stake by 152.6% as per its latest SEC filing. The fund added 3,824,899 shares during the reporting period, bringing its total to 6,331,001 shares valued at approximately $8.17 million.

What Changed in RTW Investments' Milestone Pharmaceuticals Position

RTW Investments significantly increased its position in Milestone Pharmaceuticals, adding 3,824,899 shares to its portfolio. This move took its total holdings to 6,331,001 shares, representing a 152.6% increase from its previous count of 2,506,102 shares. The total value of RTW's stake is now about $8.17 million, reflecting a strong vote of confidence in the company.

Other Institutional Activity in Milestone Pharmaceuticals

In other institutional activity, Propel Bio Management, LLC maintained its position with 4,118,321 shares valued at $5,081,571. Two Sigma Investments, LP increased its holdings by 802,715 shares, ending with 2,317,176 shares worth about $2,757,439. Goldman Sachs Group Inc made a new entry with 2,000,025 shares valued at $2,380,030. Marshall Wace, LLP added 287,709 shares to hold 1,944,530 shares valued at $2,313,991, while Millennium Management LLC significantly boosted its stake by 1,141,690 shares to hold 1,544,325 shares worth $1,837,747.

Milestone Pharmaceuticals Inc. Stock Up 11.2%

Shares of Milestone Pharmaceuticals (NasdaqGS: MIST) traded near $1.29. The company has a market cap of approximately $160.6 million. It operates with a forward P/E ratio that isn't meaningful due to its lack of profitability, and a beta of 0.965. The stock's 52-week range is between $1.00 and $3.06, with a 50-day moving average of $1.66 and a 200-day moving average of $1.87. Milestone has a strong current ratio of 9.179 and a quick ratio of 9.034, though it carries a high debt-to-equity ratio of 380.948.

Recent Earnings

Milestone Pharmaceuticals reported revenue of $1.78 million. However, the company is not yet profitable, as indicated by a net margin of 0.0 and a return on equity of -4.57%. The next earnings report is expected on August 12, 2026.

Insider Buying and Selling at Milestone Pharmaceuticals Inc.

On June 10, 2026, several insiders, including Michael John Tomsicek, Robert James Wills, Andrew Saik, Joseph Papa, Lisa Giles, and Stuart Duty, each purchased 77,000 shares. These transactions were not under any pre-planned trading programs.

Analysts Set New Price Targets

On May 14, 2026, Wells Fargo maintained its 'buy' rating for Milestone Pharmaceuticals with a price target of $7. The consensus among analysts is positive, with a mean target price of $6.33 based on six analyst opinions.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montreal, Canada. It focuses on developing and commercializing cardiovascular medicines in the U.S. and Canada. The company is known for its CARDAMYST nasal spray, used to treat episodes of paroxysmal supraventricular tachycardia. Milestone is also working on applications for atrial fibrillation. With a small team of 38 employees, the company is led by CEO Joseph G. Oliveto.

Bottom Line

RTW Investments' recent move to increase its stake in Milestone Pharmaceuticals suggests confidence in the company's potential. While 13F filings are backward-looking, they offer a glimpse into the investment strategies of major funds. Investors often monitor such filings to gauge institutional sentiment and market trends.